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Abstract
Background: Prolonged neonatal exposure to hyperoxia is associated with high mortality, leukocyte influx in airspaces, and
impaired alveolarization. Inhibitors of type 4 phosphodiesterases are potent anti-inflammatory drugs now proposed for lung
disorders. The current study was undertaken to determine the effects of the prototypal phosphodiesterase-4 inhibitor
rolipram on alveolar development and on hyperoxia-induced lung injury.
Methodology/Findings: Rat pups were placed under hyperoxia (FiO2.95%) or room air from birth, and received rolipram or
its diluent daily until sacrifice. Mortality rate, weight gain and parameters of lung morphometry were recorded on day 10.
Differential cell count and cytokine levels in bronchoalveolar lavage and cytokine mRNA levels in whole lung were recorded
on day 6. Rolipram diminished weight gain either under air or hyperoxia. Hyperoxia induced huge mortality rate reaching
70% at day 10, which was prevented by rolipram. Leukocyte influx in bronchoalveolar lavage under hyperoxia was
significantly diminished by rolipram. Hyperoxia increased transcript and protein levels of IL-6, MCP1, and osteopontin;
rolipram inhibited the increase of these proteins. Alveolarization was impaired by hyperoxia and was not restored by
rolipram. Under room air, rolipram-treated pups had significant decrease of Radial Alveolar Count.
Conclusions: Although inhibition of phosphodiesterases 4 prevented mortality and lung inflammation induced by
hyperoxia, it had no effect on alveolarization impairment, which might be accounted for by the aggressiveness of the
model. The less complex structure of immature lungs of rolipram-treated pups as compared with diluent-treated pups
under room air may be explained by the profound effect of PDE4 inhibition on weight gain that interfered with normal
alveolarization.
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Introduction
Despite recent major advances in perinatal care, very premature
infants remain prone to bronchopulmonary dysplasia (BPD), a
chronic lung disease. BPD is mainly related to an arrest of lung
development, characterized by minimal capillary development
and fewer enlarged alveoli [1,2]. Treatments to prevent or
alleviate BPD are limited, and no currently available therapy
addresses unequivocally these unmet medical needs. New
therapeutic strategies are therefore necessary to maintain harmo-
nious alveolar development and prevent BPD.
Alveolarization and distal pulmonary vascular development are
intricate events that are affected by a number of insults, including
prenatal or postnatal infections, inspired oxygen fraction, and
mechanical ventilation [3]. A final common pathway for many of
these insults is initiation and persistence of inflammation in
immature lungs [4]. Increased concentrations of cytokines and
leukemoid reaction have been detected in amniotic fluid and
tracheal aspirate from newborns who subsequently developed
BPD [5,6]. Polymorphonuclear neutrophils invade airspaces
within hours after birth and persist during the first weeks of life
in the airways of these infants [7,8]. Animal studies have
demonstrated that neutrophil-induced airway inflammation pro-
motes an arrest of alveolarization, and that inhibiting the
neutrophil influx preserves alveolar development in hyperoxia-
exposed newborn rats, an experimental model of BPD [9].
Elevated cAMP level suppresses the activity of immune,
inflammatory, and epithelial lung cells and inhibits airway
remodeling [10]. cAMP is metabolized by cyclic nucleotides
phosphodiesterases (PDEs). Among the eleven families of PDEs,
the PDE4 family represents the major cAMP-metabolizing
enzymes in all immunocompetent cells [10,11]. PDE4 inhibitors
are active in a broad spectrum of pulmonary inflammation models
and are considered as novel anti-inflammatory drugs in lung
disorders [12,13].
We therefore hypothesized that inhibition of PDE4 could
prevent inflammation and hence the subsequent alveolarization
impairement, and potentially oxygen-induced mortality. We used
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the hyperoxia model of BPD to test this hypothesis. We
investigated the effect of the PDE4 selective inhibitor rolipram
on airway inflammation, mortality rate, weight gain, and the
extent of alveolarization assessed by morphometric methods.
Inflammation was evaluated on day 6, a time when inflammation
is important in this model, and assessed by differential cell count
and cytokines levels in bronchoalveolar lavage (BAL) fluid and
lung tissue. Alveolarization occurs between day 4 and day 14 in rat
[14], and so is better evaluated in the second week of life. Due to
very high mortality rate in our model, we chose to study it no later
than day 10.
This issue has already been explored recently by de Visser and
colleagues [15] who found that PDE4 inhibitor therapy prolonged
median survival of hyperoxia-exposed pups, reduced alveolar
fibrin deposition, lung inflammation as evaluated by albumin
content in BAL and macrophage count in histological studies.
However, possible direct effect of PDE4 inhibition on alveolar
development was not evaluated in this study since no data were
provided for pups treated with rolipram under room air. The
present study confirms partly their data, but indicates that PDE4
inhibition presents, of its own, inhibiting effects on alveolarization.
Results
Assessment of inflammation and PDE4 activity at day 6
Inflammatory-cell count in BAL fluid. On day 6 of life,
hyperoxia increased 2.5 times the total number of inflammatory
cells in BAL (ANOVA p,0.05), and induced a preferential
recruitment of neutrophils that were increased 10 times as
compared with control group (ANOVA p,0.001). The trend of
macrophages to increase slightly was not significant (Figure 1).
Rolipram had no effect on inflammatory-cell count under air
Figure 1. Total cell, polymorphonuclear neutrophil, and macrophage counts in BAL from rat pups exposed to hyperoxia and
treated or not with rolipram. BAL fluid was collected on day 6 of life from rat pups exposed to normoxia or hyperoxia from birth and either
treated with rolipram (n = 6/group) or receiving the diluent alone (littermate controls, n = 6/group). Total and differential cell counts were performed
as described in Materials and Methods. Data are expressed as mean6sem. * Significantly different from the air-diluent group; { significantly different
from the air-rolipram group; { significant difference between oxygen-diluent and oxygen-rolipram groups.
doi:10.1371/journal.pone.0003445.g001
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condition but prevented totally the hyperoxia-induced increase in
total cell number (p,0.01), and prevented partly the neutrophil
increase (p,0.01).
Chemokine and cytokines. Overall, the expression levels of
the studied cytokines, considering either mRNAs or proteins, were
different among all groups (p,0.01 for each parameter by Kruskall-
Wallis analysis). On day 6 of life, hyperoxia induced a huge increase
in the protein and mRNA concentrations of IL6, MCP-1, and OPN
(Figures 2–3, p,0.05 to p,0.01 by Mann-Whitney U test
depending of the parameter). Rolipram administration under air
condition affected the protein or mRNA concentrations of none of
these factors. By contrast, it prevented the increase of MCP-1 and
OPN proteins under hyperoxia (p,0.01 between groups O2-diluent
and O2-rolipram for both). As regards IL-6, the decrease of protein
level did not reach significance (p= 0.08). Rolipram diminished the
OPN mRNA level only under hyperoxia (p,0.05 between groups
O2-rolipram and O2-diluent), although this was nevertheless higher
than in the control group (p,0.01 between groups air-diluent and
O2-rolipram).
PDE4 activity and expression. On day 6 of life, whole-lung
PDE4 activity was significantly different among all groups (p,0.05
by Kruskall-Wallis analysis). PDE4 activity tended to be higher in
the O2-diluent group as compared with the air-diluent group,
although this did not reach significance (p= 0.08) (Figure 4).
Treatment with rolipram had no effect on PDE4 activity in
normoxia, whereas it decreased it under hyperoxia (p,0.05). PDE4
family is encoded by four genes designated A through D. Whereas
PDE4C is absent from adult lungs, PDE4A, 4B, and PDE4D RNAs
are expressed in lungs [16]. Immunoblotting with antibodies raised
against PDE4A, PDE4B, and PDE4D proteins evidenced only a
slight increase of the immunosignal of a PDE4B band with an
apparent molecular weight of 72 kDa (insert in Figure 4).
Figure 2. Concentration of selected chemokine (MCP1) and cytokines (IL-6 and OPN) in BAL of rat pups exposed to hyperoxia and
treated or not with rolipram. Concentrations of MCP-1, IL-6, and OPN were measured by multiplex ELISA in BAL fluid, collected at day 6 of life
from rat pups exposed to normoxia or hyperoxia from birth and either treated with rolipram (n= 4 or 5/group) or receiving the diluent alone
(littermate controls, n = 4 or 5/group). Data are expressed as mean6sem. * Significantly different from the air-diluent group; {significantly different
from the air-rolipram group; { significant difference between oxygen-diluent and oxygen-rolipram groups.
doi:10.1371/journal.pone.0003445.g002
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Assessment of survival, growth and alveolarization at day
10
Survival. Overall, differences among all groups were
significant (p,0.001 by Logrank). In keeping with previous
studies, hyperoxia induced high mortality, mainly on days 5 and
6 of exposure, reaching 70% in the O2-diluent group (Figure 5).
Rolipram reduced hyperoxia-induced mortality to 17%, (p,0.05
between rolipram-treated and diluent-treated groups in
hyperoxia). The differences in survival between rat pups treated
by rolipram under hyperoxia and those under air and receiving
either rolipram or its diluent were not significant.
Body-weight gain. Gain in body weight was different among
all groups (p,0.001 by ANOVA). Hyperoxia impaired weight
gain of pups all over the 10 first days of life (Figure 6). Rolipram
administration decreased weight gain either under hyperoxia or
normoxia in the same proportions. The decrease induced by
rolipram was larger than that consecutive to hyperoxia exposure,
the day-10 body weight being decreased about one third.
Figure 3. Steady-state mRNA levels of selected chemokine (MCP1) and cytokines (IL-6 and OPN) in whole lungs of rat pups exposed
to hyperoxia treated with rolipram. Relative concentrations of MCP-1, IL-6, and OPN mRNAs were determined by real-time RT-PCR in whole
lungs collected on day 6 of life from rat pups exposed to normoxia or hyperoxia from birth and either treated with rolipram (n = 4 or 5/group) or
receiving the diluent alone (littermate controls, n = 4 or 5/group). Data are expressed as mean6sem. * Significantly different from the air-diluent
group;{significantly different from the air-rolipram group; { significant difference between oxygen-diluent and oxygen-rolipram groups.
doi:10.1371/journal.pone.0003445.g003
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Lung Morphometry
Gross light-microscopy evaluation of 10-day-old rat lungs
suggested that hyperoxia induced enlargement of alveoli, in the
diluent-treated as well as in the rolipram-treated groups (Figure 7).
Alveoli appeared also underdeveloped in the air-rolipram group.
The results of morphometric analysis are summarized in
Table 1.
a) Lung volume: overall, lung volume and specific lung volume
were different among all groups (p,0.05 and p,0.01,
respectively, by Kruskall-Wallis analysis). Hyperoxia de-
creased lung volume in pups treated by rolipram as well as
Figure 4. PDE4 activity in whole lung homogenates of rat pups
exposed to hyperoxia and treated or not with rolipram. Rat
pups exposed to normoxia or hyperoxia from birth and treated with
rolipram, (n = 5/group), and their littermate controls treated with
diluent alone (n = 6/group) were killed on day 6 of life. Whole lungs
were dissected out and homogenized as described in Materials and
Methods, and cAMP-PDE activity was measured in the absence or the
presence of 10 mM rolipram. Data are expressed as mean6sem. {
Significantly different from the air-rolipram group; { significant
difference between oxygen-diluent and oxygen-rolipram groups.
Upper insert: Western blot of PDE4 proteins in whole lung of rat
pups exposed to normoxia or hyperoxia from birth, and either treated
with rolipram (+) or receiving the diluent alone (2); pups were killed on
day 6 of life. Aliquots of lung homogenates with equivalent protein
amount were subjected to 8% SDS-PAGE and immunoblotted with
specific anti-PDE4A, PDE4B or PDE4D antibodies. This immunoblot is
representative of 3 separate experiments with two different animals/
group/experiment, 6 different animals/group. A loading control was
performed with a specific anti-beta actin antibody.
doi:10.1371/journal.pone.0003445.g004
Figure 5. Survival of rat pups exposed to hyperoxia and
treated or not with rolipram. Kaplan-Meier curve representation of
survival of rat pups exposed to normoxia (room air) or hyperoxia (Fi
O2.95%) (circles and triangles, respectively), and either treated with
rolipram (n= 12/group, open symbols) or receiving the diluent alone
(littermate controls, n = 13/group, closed symbols).* Significantly
different from air-diluent group curve, logrank test, p = 0.017.
doi:10.1371/journal.pone.0003445.g005
Figure 6. Growth of rat pups exposed to hyperoxia and treated
or not with rolipram. Growth curves of rat pups exposed to normoxia
or hyperoxia (circles and triangles, respectively), and either treated with
rolipram (open symbols) or receiving the diluent alone (littermate
controls, closed symbols). Values are mean6sem. Sixteen to 21 rat pups
were included on day 0. * Significantly different from air-diluent group;
{ significantly different from air-rolipram group. Note that except for
day 1 and day 2, all values of rolipram-treated pups were significantly
lower than those of oxygen-diluent-treated pups.
doi:10.1371/journal.pone.0003445.g006
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in those receiving the diluent (p,0.05 for each by Mann-
Whitney U test), but did not alter specific lung volume.
Rolipram had no effect on absolute lung volume, but
increased specific lung volume (p,0.01) either under
hyperoxia or air (p,0.01).
b) Alveolar surface: overall, alveolar-surface density, absolute and
specific alveolar-surface areas were significantly different
among all groups (p,0.001 for both by Kruskall-Wallis
analysis). As expected, hyperoxia decreased drastically the
alveolar surface density by 33%, as well as the absolute and
specific surface areas by 44% and 37%, respectively (p,0.01
for rolipram- and diluent-treated pups). Rolipram had no
effect on alveolar-surface area density but decreased absolute
alveolar-surface area in air-exposed pups by 17% (p,0.05)
and by 22%, in O2-exposed pups, although this effect did not
reach significance (p = 0.06). Rolipram increased specific
alveolar-surface area by 20% in air-exposed pups (p,0.01),
and by 22% in those under hyperoxia (p,0.05) as compared
to O2-diluent group, but this value remained lower than in
groups under air (p,0.05).
c) Parenchymal alveolar volume: overall, the differences were not
significant for volume density but were significant for absolute
and specific values between groups (p,0.05 and p,0.001,
respectively). Absolute values were decreased by hyperoxia in
both diluent (by 19%) and rolipram groups (by 14%) (p,0.05
for each), but rolipram had by itself no effect on absolute
volume, neither in air nor under hyperoxia. Hyperoxia
altered specific parenchymal volume neither in rolipram nor
in diluent groups. Rolipram increased specific values under
hyperoxia by 38% and in air by 49% (p,0.01 for each).
d) Radial alveolar count (RAC): overall, differences were significant
for RAC among groups (p,0.01). Hyperoxia decreased
significantly RAC in diluent-treated pups by 49% (p,0.01)
and in rolipram-treated pups by 35% (p,0.05). Rolipram
decreased RAC in air-exposed pups by 35% (p,0.01), but
induced no further change in hyperoxia-exposed pups.
Discussion
In the present study, we report that inhibition of PDE4s by
rolipram in rat pups exposed to hyperoxia improved survival,
decreased lung inflammation as assessed by inflammatory cell
count in airspaces and cytokine measurement, but did not prevent
hyperoxia-induced impairment of alveolarization. Most impor-
tantly, we evidence that rolipram presented by itself deleterious
effects in normoxia, including decreased weight gain and defective
alveolarization, which had not yet been reported.
Figure 7. Lung histological appearance showing effects of hyperoxia and rolipram on airspace formation in rat pups. Rat pups were
placed under normoxia (room air, A, B) or hyperoxia (Fi O2.95%, C, D) from day 0 to day 10 while receiving rolipram (B, D) or diluent (A, C). After
fixation at constant pressure, lungs were embedded in paraffin, and 3 mm thick tissue slices were cut throughout the entire lung samples and stained
with hematoxylin, phloxine and safran. Photographs of the alveolar region, taken at the same magnification, are presented for each treatment group
(bar in C represents 50 mm). Rat pup lungs under hyperoxia exhibited a diffuse, simplified lung structure with enlarged airspaces and fewer secondary
septa. Rolipram did not prevent this effect.
doi:10.1371/journal.pone.0003445.g007
Alveolar Development and PDE4
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Similar to our previous study [17], we studied inflammation at
day 6 and alveolarization and mortality at day 10. The choice of
day 6 for assessing inflammation is based on the demonstration by
Deng et al. [18] that inflammation, as evaluated by accumulation
of inflammatory cells in BAL, begins rapidly after initiating
hyperoxic exposure and increases with the duration of exposure
with a marked significant increase at day 6. Therefore, choosing
this stage allowed accurate evaluation of inflammation and its
inhibition to be performed at a time when mortality was not yet
extensive. Because on the one hand alveolar septation occurs
between day 4 and day 14 in the rat pup [14], and is therefore
already patent on day 10, and on the other hand mortality became
excessive beyond day 10, this stage was chosen to evaluate
mortality rate and perform lung morphometric analysis.
Prolonged survival of rat pups under hyperoxia has previously
been described with pentoxyfiline (PTX), a nonselective inhibitor
of PDEs [19], and more recently with rolipram at a concentration
lower than that used herein, as well as with an other PDE4
selective inhibitor, piclamilast [15]. By contrast, PTX treatment
did not prolong survival in adult rats after exposure to 95% oxygen
[20]. This may be explained by the difference in tolerance to
oxygen between neonatal and adult animals. Rolipram is the
prototypal PDE4 selective inhibitor, first described more than
three decades ago [21], and it is generally admitted that at the
dosage used in this study, rolipram has minimal inhibitory effect
on other PDE families and does not interfere with unrelated
signalling pathways [11]. A new generation of selective PDE4
inhibitors that includes piclamilast has been developed, with
progress mainly in pharmacokinetics, albeit they reproduce with
constancy the previously described in vitro and in vivo effects of
rolipram [22,23]. Thereby, results observed with PTX or
piclamilast are certainly related to the capacity of these molecules
to inhibit PDE4s. It should be pointed out that de Visser et al. [15]
reported, as the result of a pilot experiment, a mortality rate of
33% for pups under hyperoxia and treated with rolipram 0.5 mg/
kg/d, whereas we observed decreased mortality under hyperoxia
with this dose. The choice of the latter in the present study is based
on our preliminary observations that pups in room air presented
high mortality rate with higher doses of rolipram, whereas
minimal systemic PDE4 inhibition was achieved at doses below
0.5 mg/kg/d. Strain differences in susceptibility to oxygen and
rolipram as well as those in initial weight may account for
differences in findings between investigations. We indeed observed
that rolipram-induced mortality was higher in thinnest pups. Since
in the previous investigation [15], pups were about 2 grams lighter
than those in our study on day 1, this represents a likely
explanation of the different mortality rates between them.
The precise mechanisms by which PDE4 inhibition confers
protection against lethal hyperoxia are still unclear. The role of
PDE4s in the response to hyperoxia has been poorly studied. It has
been demonstrated that hyperoxia, as well as hypoxia, increased
blood level of PDEs [24] especially in young rats, but this was not
correlated to mortality. We found a tendency towards higher
PDE4 activity levels after hyperoxia for 6 days in lung tissue
homogenates, and reported an increase of a 72 kDa PDE4B
protein, presumably PDE4B2 [25]. PDE4A and PDE4D isoforms
were not modified by hyperoxia. Because PDE4 activity is high
and PDE4B2 is constitutively expressed in neutrophils [26], this
may be related to the lung influx and sequestration of neutrophils
induced by hyperoxia in the first week of life. PDE4 has been
implicated in the adhesion of neutrophils to endothelial cells, their
chemotaxis, and the production of oxidative burst [22]. In this
view, the fact that we documented here a significant decrease in
neutrophil count in BAL from rolipram-treated pups associated
with a significant decrease of PDE4 activity suggests a specific role
for PDE4 in oxygen toxicity. Oxygen insult drives a chronic
inflammation involving free radicals, arachidonic acid metabolites,
cytokines, chemokines, and recruitment and activation of
neutrophils with a further production of reactive substances that
react rapidly with proteins, carbohydrates and lipids, thus
Table 1. Morphometric measurements.
AIR HYPEROXIA
Diluent rolipram Diluent rolipram
(n=6) (n=6) (n =6) (n=6)
Body weight at day 10(g) 23.562.3 16.661.7* 19.962.4{ 12.761.48*{{
Lung volume (cm3) 1.2660.17 1.1260.10 1.0160.22* 0.9760.06*{
Specific lung volume (cm3/100 g) 5.0160.35 6.8160.43* 4.4961.10{ 7.1561.05*{
Alveolar surface
Area density (cm2/cm3) 248615 229630 167630*{ 145620*{
Absolute area (cm2) 287634 237633* 162634*{ 127613*{
Specific area (cm2/100 g) 1143687 14446196* 7196222*{ 9246106*{{
Alveolar Parenchyme (Vvp)
Volume density (%) 9660.5 9661.4 9761.0 9561.5
Absolute volume (cm3) 1.2160.16 1.0760.09 0.9860.22* 0.9260.06*{
Specific volume (cm3/100 g) 3.960.4 5.960.7* 4.360.5{ 7.060.7*{
Radial Alveolar Count
RAC (n) 10.560.8 6.961.8* 5.461.3* 4.560.6*{
Values are mean6SD.
*significantly different from the air-diluent group.
{significantly different from the air-rolipram group.
{significant difference between oxygen-diluent and oxygen-rolipram groups.
doi:10.1371/journal.pone.0003445.t001
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disrupting intercellular and intracellular homeostasis [27]. The
drastic decrease of neutrophil sequestration in airspaces consec-
utive to rolipram treatment may thus account for its advantage for
survival.
Although we did not address directly the question of oxidative
stress, we determined the protein level in BAL and mRNA level in
tissue of the key pro-inflammatory chemokine and cytokine MCP-
1 and IL-6 to document airway inflammation. These two
mediators have been shown to be elevated during hyperoxia
[28], and neutralization of MCP-1 alleviated lung oxidant injury
[29]. Rolipram treatment decreased significantly the accumulation
of these proteins in BAL, although it did not diminish the increase
of their mRNAs. This latter finding is discrepant with the study by
de Visser and collaborators [15] who showed significant decrease
of MCP-1 and IL-6 mRNAs on day 10 of exposure. Differences in
timing of PDE4 inhibition between their and our experiments may
explain this difference. The fact that these mediators were affected
by rolipram only at the protein level might reflect the contribution
of neutrophils and rapid turnover of these proteins with absence of
accumulation in lungs. Indeed, several investigations demonstrated
though a significant PDE4-inhibition effect at the transcriptional
level in leukocytes [30], whereas alveolar epithelial cells concom-
itantly expressed cytokine mRNAs that may be poorly controlled
by PDE4s in these cells.
In addition, we also determined OPN at pre- and post
translational levels and showed a significant effect of rolipram on
both. OPN, a secreted phosphoprotein, exists both as an
immobilized ECM molecule in mineralized tissues and as a
cytokine that mediates cellular functions involved in inflammation
and ECM remodelling [31]. OPN gene expression is low during
secondary septation, a key event of alveolarization [32], increases
afterwards, and is overexpressed during neonatal hyperoxia [32]
and in pulmonary fibrosis [33], the latter being a feature
encountered to variable extent in BPD. Thus, PDE4 inhibition
exhibits a potent anti-inflammatory effect in early postnatal
period, which is consistent with other models of inflammation in
the adult and with clinical trials [12,34].
Considering the role of inflammation in the development of
BPD, we therefore expected a preventive effect of rolipram on
hyperoxia-induced lung injury, including its effects on alveolar
development. Consistent with previous experiments using the
same approach [17], alveolarization was impaired by hyperoxia,
including a significant decrease in alveolar-surface area and RAC.
This was the case, however, for diluent-treated as well as for
rolipram-treated pups, indicating that rolipram did not restore
alveolar surface area and RAC to control values. In their former
study, de Visser and coworkers [15] argued for a beneficial effect
of PDE4 inhibitors on lung histopathology because they found
decreases in septal thickness and alveolar edema despite an
absence of effect of PDE4 inhibitors on changes induced by
hyperoxia in mean linear intercept. However, our more in-depth
morphometric study together with the study of direct effects or
rolipram in pups maintained in room air lead to modulate this
interpretation. Indeed, rolipram also induced by itself a decrease of
absolute alveolar-surface area and RAC in pups maintained in air.
This appears suggestive of altered lung development, although this
conclusion must be moderated by the observation that all specific
values, i.e. when reported to body weight, were increased.
Nonetheless, defective alveolarization induced by hyperoxia was
not further impaired by rolipram. Neither area and volume
densities, nor absolute values and RAC were significantly
diminished in rolipram-treated pups under hyperoxia as compared
with hyperoxia alone. It is likely that if there were pups presenting
more extensively altered alveolarization, they could not survive
further and were thus not evaluated.
A major gross side effect that was encountered with rolipram
treatment was a significant decrease of weight gain, which is
probably responsible for at least a part of altered alveolarization.
Whereas pups maintained under hyperoxia showed a significant
reduction of body weight gain after 5 days only as compared with
those in normoxia, rolipram reduced weight gain already from the
first day of injection, and its effect encompassed that of hyperoxia.
This effect of rolipram was also observed, although to a lesser
extent, by de Visser et al. [15] with half the dose used herein, even
though they did not report data from a group treated with
rolipram in room air. Our data allow us to conclude unequivocally
to a significant effect of PDE4 inhibition independent of oxygen
exposure. Rolipram may have an adverse effects on food intake
most likely because of its adverse effects in the central nervous
system and parietal glands that account for nausea, vomiting, and
enhanced gastric acid secretion [35]. However, conversely to the
previous study [15], we did observe pups nursing properly and
gastric milk filling during the whole course of rolipram treatment
(data not shown). Toxicological reports during preclinical studies
of PDE4 inhibitors demonstrated significant inflammation of the
intestinal tract and mesenteric vascularitis that suggest ill-
absorption of food [36,37]. Clinical studies with rolipram did
not report weight loss in adult patients, the main adverse effects
being headache, nausea, dizziness, abdominal pain, and vomiting,
but it should be emphasized that the effects of PDE4 inhibitors are
unknown on an unborn child, a pregnant woman, or a nursing
infant. PDE4D knock-out mice, but not PDE4B or PDE4A knock-
out strains, present growth retardation during their first weeks of
life, catching up later in adulthood [38]. A clinical trial evaluating
the effect of caffeine, which has nonselective PDE inhibitory
properties and is widely used in neonatal intensive care units for
preventing apnea of prematurity, induced a significant weight gain
reduction in these infants, although the difference was no longer
present at two years of life [39,40]. Taken together, these
observations suggest that PDE4 inhibitors may indeed interfere
with statural growth in the early days of life.
In fact, impaired weight gain in rolipram-exposed pups seems to
be the major factor accounting for our lung morphometric results.
Massaro et al. [41] previously described a decrease in lung volume
and absolute alveolar surface area with increased specific values in
undernourished pups. The importance of nutrition in alveolar
formation is known even in adult mice, and the rapid onset of
genes involved in alveolar formation following refeeding after
caloric restriction has been highlighted recently [42]. Therefore, it
is difficult to dissociate the effect of rolipram on alveolarization
from its weight-gain altering effect, although the decrease of RAC
that directly reflects deficient alveolar septation argues for an
additional effect independent from that on overall growth.
To conclude, PDE4 inhibition by rolipram displayed a potent
inhibiting effect on hyperoxia-induced lung inflammation and
mortality, but the direct inhibiting effects of the molecule on rat
pup growth and lung development do not allow one to conclude
favourably about its possible protective effect towards impaired
lung alveolarization. Due to this side effects, it is certainly too early
to propose a therapeutic role of PDE4 inhibition in the prevention
of altered lung development. Nevertheless, the model of altered
lung development used here is extremely aggressive, and the part
of oxidant injury and inflammatory response cannot really be
distinguished. Therefore, studying PDE4 inhibition in other
models of arrested alveolarization, more purely inflammatory, as
well as the use of a local instead of a systemic route should be
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considered. Moreover, the possible involvement of PDE4s in lung
development is completely unknown and requires specific studies.
Materials and Methods
Details are available as as supporting information; see Materials
and Methods S1.
Animals and hyperoxic exposure
All animal procedures were approved by our Institutional
Committee on Animal Use and Care. Pregnant Sprague-Dawley
rats were purchased from Charles River Laboratories (Saint-
Germain sur l’Arbresle, France). Rat pups born in the laboratory
and their dams were placed in chambers (Charles River) run in
parallel under FiO2either.95% or = 21% (room air) as previously
reported, from day 0 to day 6 or 10 [17]. The dams were
exchanged daily between O2-exposed and room air-exposed litters
to avoid lethal oxygen toxicity. Rat pups were weighed every day.
Rolipram treatment
Rat pups received daily either an intraperitoneal injection of
0.5 mg/kg/d of rolipram (Sigma-Aldrich, St Louis, MI) or its
vehicle (ethanol 0.05%), hereafter referred to as the diluent. The
dose of 0.5 mg/kg/d was chosen after performing a pilot study
with i.p. doses of rolipram ranging from 0.2 to 3 mg/kg/d, which
showed high mortality at the highest doses and minimal systemic
PDE4 inhibition at the lowest doses. This dose is twice the one
used in previous study [15] in which high mortality rate was
reported for 0.5 mg/k/d.
Sample collection and bronchoalveolar lavage
Rat pups were killed by an intraperitoneal overdose of sodium
pentobarbital (70 mg/kg, Ceva, Libourne, France) and were bled
by aortic transsection. Lungs were either immediately lavaged, or
fixed for morphometric/morphologic analysis, or dropped in
liquid nitrogen and kept frozen at 280uC for further RNA
extraction or protein immunoassay. BAL was performed using a
total of 4 ml sterile saline; BAL fluid was centrifuged and total and
differential cell counts were performed.
Chemokine/Cytokine measurements in BAL
Measurements of MCP-1, IL-6, and osteopontin (OPN) protein
concentrations were performed using the SearchlightTM multiplex
sample testing by Endogen, PerbioScience (Brebieres, France).
Determination of mRNA steady-state level in lung tissue
Total RNA was extracted using TrizolTM reagent (Invitrogen,
Cergy-Pontoise, France). First-strand cDNAs were synthesized
from 2 mg of RNA using the Superscript II reverse transcriptase,
and random hexamer primers (Invitrogen). Real-time PCR was
conducted using sequence-specific primers and ‘‘18S rRNA’’ as a
reference with aid of ABI PRISMH 7000 Sequence Detection
System (Applied Biosystems, Courtaboeuf, France).
Phosphodiesterase activity and western blot analysis
Whole lung tissues were homogenized in hypotonic buffer. PDE
activity was assayed using a modification of the Thompson and
Appleman’s method [43] as described previously [44]. For western
blotting of PDE4, samples were boiled in Laemmli buffer,
subjected to SDS-PAGE, and immunoblotted with polyclonal
rabbit anti-PDE4A (AC55), polyclonal PDE4B (K118) and
monoclonal PDE4D (M3S1) antibodies as previously described
[45]. Correction for variations in loading was performed by
blotting with an antibody raised against beta-actin (Sigma, A2066).
Membranes were incubated in chemiluminescent detection
reagent (ECL, GE Healthcare Life Sciences, Velizy, France), then
exposed to KODAK BioMax MS film. Other sets of antibodies
were used for additional controls: sheep polyclonal antibodies
raised against PDE4A, PDE4B, and PDE4D [46] and gave
identical results.
Morphometry analysis
Lungs were fixed at constant pressure as described previously
[47]. Alveolar surface density (Svap) was determined using point
counting and mean linear intercept methods described by Weibel
and Cruz-Orive [48]. Absolute surface area (Sa) per lung was
calculated by multiplying surface density by lung volume. Radial
alveolar count (RAC) was also performed [49,50,51].
Statistical analysis
Multiple group comparisons were performed using either
ANOVA or Kruskall-Wallis analysis, and two-group comparisons
were made by Fishers post hoc test or Mann-Whitney U test, as
appropriate. Survival was evaluated by Kaplan-Meier survival
function and the logrank test. Calculations were performed with
StatviewH software (5.0, SAS Institute Inc, North Carolina). A P
value,0.05 was considered to be statistically significant.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0003445.s001 (0.05 MB
DOC)
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